Sydney researchers uncover cancer's silent culprit
07 April, 2004 by Graeme O'NeillTwo Sydney cancer patients have made medical history this week as the first individuals to be diagnosed with cancer induced by spontaneous silencing of an otherwise normal tumour-suppressor gene.
Billionaire gives $20 million to UQ, Foundation gives $3.3 million to cancer projects
01 April, 2004 by Graeme O'NeillIf Queensland Premier Peter Beattie fulfils his ambition of appropriating Victoria’s mantle as the Biotech State, he will be indebted to itinerant Brisbane resident Chuck Feeney.
London-Brisbane vaccine research extended to kidney cancer
01 April, 2004 by Renate KrelleHaving secured patent coverage for its vaccine technology, London-based Onyvax will extend its collaboration with researchers from the Queensland University of Technology and the Princess Alexandra Hospital.
Novogen's phenoxodiol shows promise in cancer trials
01 April, 2004 by Melissa TrudingerNovogen (ASX: NRT) has announced updated results from two clinical trials of its anti-cancer drug phenoxodiol, which is being developed by the company's US-based subsidiary Marshall Edwards (LSE AIM: MSH; Nasdaq: MSHL).
GTG awarded further patents and forensic accreditation
29 March, 2004 by Melissa TrudingerGenetic Technologies' (ASX: GTG) non-coding DNA analysis and foetal cell separation patents have been allowed by the Canadian Patent Office -- almost 15 years after the company filed its first non-coding DNA patent.
Virax raises $3.7 million in placement
26 March, 2004 by Melissa TrudingerVirax (ASX: VHL) announced this week that it had raised AUD$3.7 million through a placement to institutional and professional investors.
Prima could net $20m in deal with Canada's Biomira
11 March, 2004 by Renate KrelleCommercialisation proceeds apace at Prima Biomed, which today announced an agreement with Canadian cancer vaccine specialist Biomira.
Promics completes psoriasis pilot study
10 March, 2004 by Melissa TrudingerBrisbane-based biotechnology company Promics has completed a pilot study examining the safety of its lead anti-inflammatory drug PMX 53 as a topical treatment for psoriasis.
Flu epidemic lifts Biota revenues
27 February, 2004 by Renate KrelleShares in Biota Holdings fell more than 6 per cent yesterday, despite the company's announcement that it had reduced its operating loss by almost half, reporting a loss after tax of $3.1 million as compared to $5.5 million in 2002.
US healthcare workers lag in flu vaccines: study
26 February, 2004 by Maggie FoxHealth officials lecture Americans every year on the importance of getting an influenza vaccine but it seems they are not even able to get a majority of their colleagues to do so.
Florey researchers reveal Huntington's secrets
20 February, 2004 by Graeme O'NeillNeuroscience researchers have found evidence that environmental factors play a major role in accelerating or delaying the onset and progression of the lethal brain disorder Huntington's disease in a mouse model.
Grant to boost Prana's Alzheimer's project
19 February, 2004 by Graeme O'NeillMelbourne drug-development company Prana Biotechnology (ASX:PBT) will turn up the wick on development of its second-generation drug candidate for Alzheimer's disease PBT-2, after receiving a $1.35 million federal government R&D Start grant.
Lorne Cancer report: call for new trial parameters
17 February, 2004 by Melissa TrudingerA prominent cancer researcher has told the Lorne Cancer Conference that many experimental cancer drugs are being discarded as having no value in prolonging survival in cancer patients, but the problem may lie with the clinical trial process.
Starfish invests in Melbourne stroke spin-off
16 February, 2004 by Melissa TrudingerVC fund Starfish Ventures has made an investment into NeuProtect, a company spun out of the Howard Florey Institute, the University of Melbourne and Neurosciences Victoria to develop novel therapies for stroke and myocardial infarction or heart attack.
Acrux enters US$13m development deal
16 February, 2004 by Melissa TrudingerAcrux subsidiary FemPharm has secured a US$13.3 million deal with Californian company Vivus to develop and commercialise its transdermal spray for female sexual dysfunction and menopause.
